1 The EIC Accelerator Project

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support small and medium-sized enterprises (SMEs) and startups aiming to scale their innovations and bring groundbreaking technologies to market. The program focuses heavily on DeepTech innovations, which include advanced technologies in fields such as biotechnology, artificial intelligence, and advanced manufacturing. The EIC Accelerator provides both grant funding and equity investment, facilitating access to capital that is crucial for the growth of innovative companies.

Funding Structure

The EIC Accelerator offers a blended financing model that combines grants and equity. The grant component can reach up to €2.5 million, aimed at covering the costs of product development, including prototype development and testing. The equity component can provide up to €15 million until 2024 and has been adjusted to a maximum of €10 million from 2025 onwards. This flexible funding structure allows companies to choose the right mix of grant and equity financing based on their specific needs and growth plans.

Purpose and Role in the Ecosystem

The primary purpose of the EIC Accelerator is to bolster the European startup ecosystem, particularly in the DeepTech sector, by addressing the funding gap that many innovative companies face during their early stages. By providing necessary financial resources, the program helps startups to scale their operations, attract additional private investments, and enhance their market competitiveness. The EIC Accelerator not only provides financial backing but also offers mentoring, networking opportunities, and access to a broad range of resources that can facilitate business growth.

EIC Accelerator Winner: DoMore Diagnostics AS

DoMore Diagnostics AS, a Norwegian company, has emerged as a winner of the EIC Accelerator with its project, Histotype Px. This initiative focuses on developing a precision biomarker based on digital pathology and artificial intelligence. The goal is to enable fast and cost-effective personalized treatment decision support for colorectal cancer patients.

Project Overview: Histotype Px

Histotype Px leverages cutting-edge technologies in digital pathology and AI to analyze biopsy samples and identify specific biomarkers associated with colorectal cancer. This innovation is designed to streamline and enhance the decision-making process regarding treatment options, ultimately leading to more personalized and effective care for patients. The technology aims to address the challenges faced in traditional pathology, which can often be time-consuming and prone to variability in interpretation.

Technology Basics and Background

The technological foundation of Histotype Px rests on advanced image analysis and machine learning algorithms. Digital pathology involves the conversion of glass slides into digital images, allowing for remote analysis and sharing among healthcare professionals. AI algorithms are employed to analyze these images, identifying patterns that correlate with various cancer types and stages. By integrating biomarker discovery with AI, DoMore Diagnostics aims to create a comprehensive diagnostic tool that enhances the precision of treatment plans.

The development of this technology is particularly significant given the increasing burden of colorectal cancer, which is one of the most common cancers worldwide. Traditional diagnostic methods often lead to delays in treatment and may not adequately account for the unique characteristics of each patient's cancer. Histotype Px aims to overcome these limitations by providing timely and accurate insights that can directly inform treatment decisions.

In conclusion, the EIC Accelerator serves as a vital resource for innovative companies like DoMore Diagnostics AS. Through its blended financing model, the program not only supports the development of groundbreaking technologies but also fosters a thriving ecosystem for entrepreneurship in Europe. DoMore Diagnostics, with its Histotype Px project, exemplifies the potential impact of such funding on healthcare innovation, aiming to improve outcomes for colorectal cancer patients through precision medicine.

2 The Funding Rounds

DoMore Diagnostics AS: Funding and Financing Overview Since EIC Accelerator Award

Financing Raised

Since its successful application to the EIC Accelerator (Step 2 proposal submitted November 8, 2023), DoMore Diagnostics AS has secured significant funding:

• EIC Accelerator Grant: The company was awarded up to €10 million through the prestigious European Innovation Council (EIC) Accelerator program. This consists of a €2.5 million non-dilutive grant and up to €7.5 million in equity matching investment.
• Research Council of Norway Grants: In addition to EU funding, DoMore Diagnostics received NOK 16 million (~€1.4M) from the Research Council of Norway for innovation projects in both early 2024 and again in early 2025. These grants are dedicated to clinical validation and further development of their AI-based biomarker technology.

Funding Rounds – Timing and Amounts

• March 2024: Announcement of EIC Accelerator blended finance award — up to €10M (€2.5M grant + €7.5M equity).
• February/March 2024: Public confirmation by Oslo Cancer Cluster, with CEO Torbjørn Furuseth discussing significance for scale-up.
• February 25, 2025: New NOK 16 million public grant from the Research Council of Norway for an innovation project focused on combining AI biomarkers with ctDNA technologies.

Previous Funding Rounds

Before winning the EIC Accelerator award:

In June 2021, DoMore Diagnostics raised NOK 15 million (~€1.45M at then-current rates) from Norwegian investment firm Norselab and angel investor Øyvind Grotmol. No subsequent disclosure suggests a Series A or B round between this pre-seed/seed round and their EIC award.

Investor Information

Key investors include:

• Norselab (Norwegian venture fund)
• Øyvind Grotmol, private angel investor

The structure for future equity matching under the EIC is not disclosed publicly as of May 2025; thus, no additional investors have been confirmed as part of post-EIC rounds.

Company Valuations

No public information is available regarding company valuations following any funding rounds or after receiving blended finance via the EIC Accelerator program.

Exit Events: IPOs or Acquisitions

As of May 6, 2025:

There have been no reported exit events such as initial public offerings (IPOs), buyouts, or acquisitions involving DoMore Diagnostics AS.

The company remains privately held with continued growth supported by strategic grants and pending potential future private investments associated with its scaling phase.

---

Sources

• DoMore Diagnostics secures EIC Accelerator grant - awarded up to €10M
• News — DoMore Diagnostics
• DoMore Diagnostics secures EUR 10 million grant
• DoMore Diagnostics secures NOK 16 mill grant for a new innovation project
• DoMore Diagnostics to raise NOK 15 million from Norselab and Øyvind Grotmol

3 The Press Releases

DoMore Diagnostics AS: Recent Developments and Achievements

DoMore Diagnostics AS, a Norwegian company, has been making significant strides in the field of personalized cancer treatment since receiving the EIC Accelerator funding in November 2023. The company was awarded up to €10 million in grant and equity financing to support key milestones leading to the commercial launch and scale-up of its digital biomarker, Histotype Px® Colorectal.

Technology Advancements

Histotype Px® Colorectal: This AI-powered tool analyzes digital histology slides to assess the risk of recurrence in colorectal cancer patients, helping determine whether additional chemotherapy after surgery is necessary. It aims to personalize treatment decisions, reducing unnecessary side effects and healthcare costs.

Partnerships

• University Medical Centre Utrecht (UMC Utrecht): DoMore Diagnostics has collaborated with UMC Utrecht to validate its digital biomarker, Histotype Px® Colorectal, for personalized cancer treatment in colon cancer.
• Paige: The company has entered a commercial partnership with Paige to make Histotype Px® Colorectal available on Paige’s AppLab™ Marketplace.
• Stavanger University Hospital: Collaboration is underway to validate the Histotype Px® Colorectal biomarker in Norwegian stage II/III colorectal cancer patients.

Awards and Recognition

• AI Startup of the Year: DoMore Diagnostics was named "AI Startup of the Year" by the Norwegian Artificial Intelligence Research Consortium (NORA).
• Additional Funding: Apart from the EIC funding, the company received NOK 16 million from the Research Council of Norway for clinical validation and implementation of its AI-based digital biomarker.

Team Updates

Goran Kovačević: Recently joined as Senior Software Developer, contributing to the development of secure cloud systems.

Press Releases and Updates

The latest updates and press releases are available on the company's website, detailing its progress in AI-driven cancer diagnostics and partnerships.

Sources

• DoMore Diagnostics News
• DoMore Diagnostics Secures EIC Accelerator Grant
• DoMore Diagnostics Secures EUR 10 Million Grant
• DoMore Diagnostics Uses AI to Personalize Cancer Treatment
• Company Overview - DoMore Diagnostics

4 The Technology Advancements

DoMore Diagnostics AS: Post-EIC Accelerator Funding Advancements and Market Traction

Since securing the EIC Accelerator grant of up to €10 million in March 2024 (), DoMore Diagnostics AS has accelerated its AI-driven precision oncology initiatives, focusing on clinical validation, technology enhancements, and strategic collaborations. The company’s flagship product, Histotype Px® Colorectal, remains central to its mission of reducing overtreatment in stage II/III colorectal cancer (CRC) through AI-powered digital biomarkers.

Technological and Clinical Advancements

• U.S. Cohort Study: Results from a validation study at Ohio State University were presented at the 2024 ASCO Annual Meeting, confirming applicability in U.S. patient cohorts.
• Danish Collaboration: A partnership with Aarhus University Hospital (January 2025) aims to validate Histotype Px in a large Danish cohort with comprehensive ctDNA monitoring.

Market Demonstration and Trials

• Stavanger University Hospital Pilot: Testing clinical utility within Norway’s ACROBATICC study framework to optimize adjuvant chemotherapy decisions.
• UMC Utrecht Collaboration: Joint research to validate Histotype Px in European CRC cohorts, emphasizing real-world clinical integration.

Intellectual Property and Publications

While no new patents are explicitly disclosed post-EIC funding, peer-reviewed validations continue through partnerships:

• The Lancet Oncology-published methodology underpins CE-IVDD certification for Histotype Px® Colorectal.
• Ongoing trials focus on health-economic impact assessments critical for regulatory approvals in Europe and the U.S..

---

Sources

• DoMore Diagnostics secures NOK 16 mill grant
• EIC Accelerator grant announcement
• ASCO Annual Meeting presentation
• Aarhus University Hospital collaboration
• Paige partnership details

5 The Partnerships and Customers

DoMore Diagnostics AS: Strategic Partnerships and Market Positioning Post-EIC Accelerator Funding DoMore Diagnostics AS, a Norwegian precision diagnostics company, has established multiple strategic partnerships to advance its AI-driven digital biomarkers for cancer treatment. Below is an analysis of key collaborations, customers, and market positioning based on recent activities:

---

Key Partners and Collaborations

• Proscia: Integrated DoMore’s Histotype Px® Colorectal biomarker with Proscia’s Concentriq® Dx platform to streamline AI-powered clinical decision support in colorectal cancer (CRC) workflows.
• Paige: Added Histotype Px® Colorectal to Paige’s AppLab™ Marketplace, enabling pathologists to deploy the biomarker within Paige’s FDA-approved platform.
• Sectra: Embedded Histotype Px® Colorectal into Sectra’s Amplifier Marketplace for seamless access within existing pathology workflows.
• PathAI: Integrated DoMore’s biomarker into PathAI’s AISight Image Management System (IMS), providing pathologists with AI-generated overlays and quantitative insights directly in their workflows.
• Aarhus University Hospital (AUH): Launched a large-scale clinical collaboration in January 2025 to validate Histotype Px® alongside circulating tumor DNA (ctDNA) monitoring in CRC patients, enhancing prognostic accuracy.

---

Customers

While specific customer names are not disclosed publicly, DoMore targets leading diagnostic laboratories and healthcare providers adopting digital pathology solutions. Key indicators:

• Partnerships with Proscia, Paige, and Sectra suggest access to their global client networks.
• Collaboration with AUH positions DoMore as a provider for large academic medical centers leveraging AI-powered diagnostics.

---

Nature of New Relationships

Recent collaborations focus on two objectives: (1) integrating Histotype Px® into existing digital pathology ecosystems (e.g., PathAI AISight), and (2) validating its predictive power through real-world clinical studies (e.g., AUH partnership). These efforts aim to reduce overtreatment by personalizing CRC therapy based on AI-driven risk stratification.

---

Market Positioning and Scaling Impact

3. Scalability: Cloud-based deployment through AppLab™ Marketplace reduces implementation costs while increasing accessibility.

---

Sources Used

• DoMore Diagnostics And Proscia Partner To Inform Personalized Treatment Decisions [Proscia Partnership]
• DoMore-AUH Clinical Collaboration [AUH Study Details]
• Partners - DoMore Diagnostics [Sectra & Paige Integrations]
• PathAI's Integration Announcement

"PathAi link corrected manually due source formatting error; original URL contained double hyphens." ```markdown Corrected URL: https://www.pathai.com/resources/pathai–announces-integrations-with-leading–ai-pathology-companies-deep-bio-domore-diagnostics-paige-and-visiopharm-through–its–aisight-image-management-system/ ``` (Note: Replace "--" with "-" if hyperlink fails)

---

Additional sources referenced but not directly quoted include company website sections (domorediagnostics.com) and funding-related interviews (42plus1 winner interview).

6 The Hiring and Company Growth

DoMore Diagnostics AS: Team Growth and Scaling Efforts Post-EIC Accelerator Funding DoMore Diagnostics AS, a Norwegian AI-driven cancer diagnostics firm, has shown consistent growth in team size and capabilities following its 2023 EIC Accelerator win. While the company’s exact current headcount remains undisclosed, publicly available data indicates it operates with 2–10 employees, though recent funding rounds and project expansions suggest ongoing hiring to support its global scaling ambitions.

Hiring and Team Expansion

In 2021, DoMore raised NOK 15 million (€1.3 million) from Norselab and entrepreneur Øyvind Grotmol to accelerate international expansion. The company emphasized plans to recruit an "A-team" during this phase, targeting experts in AI, pathology, and commercial operations to drive product development and market entry. By early 2025, DoMore secured an additional NOK 16 million grant from Norway’s Research Council for a colorectal cancer biomarker project, further underscoring the need for specialized talent in clinical validation and algorithm development.

Key Positions and Strategic Hires

While specific recent hires are not detailed publicly:

• Leadership roles: The management team includes CEO Torbjørn Furuseth (ex-McKinsey) Director Yngve Tvedt (Norselab founder), Prof. Knut Liestøl (AI/statistics expert), with no reported changes since late 2023.
• Technical focus: Recruitment likely targets AI engineers, pathologists, regulatory specialists for CE-IVDD compliance, given the company’s emphasis on commercializing its Histotype Px® Colorectal biomarker globally.

Growth Trajectory Post-Funding

The EIC Accelerator funding aligns with DoMore’s strategy to validate its AI biomarkers across multiple cancer types while expanding into European healthcare systems. New team members would enable:

• Clinical validation: Collaboration with Oslo University Hospital on minimal residual disease detection via combined histopathology/ctDNA analysis.
• Regulatory scaling: Faster certification processes for lung/prostate cancer applications of Histotype Px®.

No major management changes have been reported since its 2020 founding or post-2023 EIC award period.

---

Sources

• Company — DoMore Diagnostics
• Better cancer prognostics using AI: Norselab invests in DoMore
• Domore Diagnostics As - Development Aid

Lancet study citations are referenced but not directly linked per guidelines; institutional collaborations confirmed via official announcements (Novel AI-based biomarker grant).

7 The Media Features and Publications

DoMore Diagnostics AS: Media Coverage, Events, and Industry Engagement DoMore Diagnostics AS, a Norwegian AI-driven cancer diagnostics company and EIC Accelerator grant recipient (up to €10 million awarded), has garnered significant attention through media features, clinical collaborations, and event participation since securing funding in late 2023. Below is a synthesis of their public engagements post-EIC award:

Media Features & Publications

• "AI Startup of the Year" Recognition: Named by the Norwegian Artificial Intelligence Research Consortium (NORA) for pioneering AI-based cancer diagnostics[^domore_news][^domore_homepage].
• Oslo Cancer Cluster Spotlight: Featured in a startup profile highlighting Histotype Px® Colorectal’s potential to reduce overtreatment in colorectal cancer[^domore_news].
• MassDevice Coverage: Reported CE mark approval for Histotype Px® Colorectal as the first AI tool predicting outcomes from routine pathology slides[^massdevice].

Podcasts & Interviews

42plus1 Pitch Competition Interview: CEO Torbjørn Furuseth discussed their seed funding success and plans for global regulatory approvals after winning Europe’s 2024 pitch competition[^42plus1].

Conference Presentations & Collaborations

• ESMO 2024 Congress: Presented a study with Japan’s National Cancer Center validating Histotype Px® combined with ctDNA in over 1,000 colon cancer patients[^esmo_poster].
• ASCO Annual Meeting 2024: Shared U.S. validation data for Histotype Px® via Ohio State University collaboration[^domore_news].
• Strategic Partnerships: Announced research collaborations with Aarhus University Hospital (Denmark) and UMC Utrecht (Netherlands) to validate their biomarker across diverse patient cohorts[^domore_news][^umc_collab].

Event Participation

DxPx Conference 2024: Showcased at the European diagnostics event following their pitch competition win[^42plus1].

---

Sources Used:

• News — DoMore Diagnostics – Funding announcements, collaborations, awards.
• DoMore Diagnostics homepage – Company overview and accolades.
• MassDevice: CE Mark Approval – Regulatory milestone coverage.
• 42plus1 Winner Interview – Post-pitch competition insights.

+ ESMO 2024 Poster Details – Clinical validation data release.